The cyclooctadepsipeptide anthelmintic emodepside differentially modulates nematode, insect and human calcium-activated potassium (SLO) channel alpha subunits by Crisford, A. et al.
RESEARCH ARTICLE
The Cyclooctadepsipeptide Anthelmintic
Emodepside Differentially Modulates
Nematode, Insect and Human Calcium-
Activated Potassium (SLO) Channel Alpha
Subunits
Anna Crisford1☯, Ulrich Ebbinghaus-Kintscher2☯, Eva Schoenhense2¤a, Achim Harder3¤b,
Klaus Raming2, Ita O’Kelly4, Kelechi Ndukwe1¤c, Vincent O’Connor1, Robert J. Walker1,
Lindy Holden-Dye1*
1 Centre for Biological Sciences, University of Southampton, Southampton, United Kingdom, 2 Bayer
CropScience Aktiengesellschaft, BCS AG-R&D-SMR-PC-PCB-PB, Monheim, Germany, 3 Bayer Animal
Health GmbH, BHC-GDD-AH-PARA-AR, Monheim, Germany, 4 Faculty of Medicine, Southampton General
Hospital, Southampton, United Kingdom
☯ These authors contributed equally to this work.
¤a Current address: University of Bonn, Bonn, Germany
¤b Current address: Institute for Biology, Heinrich-Heine-University, Düsseldorf, Germany
¤c Current address: Department of Biological Sciences, Lehman College, City University of New York, West
Bronx, New York, New York, United States of America
* lmhd@soton.ac.uk
Abstract
The anthelmintic emodepside paralyses adult filarial worms, via a mode of action distinct
from previous anthelmintics and has recently garnered interest as a new treatment for
onchocerciasis. Whole organism data suggest its anthelmintic action is underpinned by a
selective activation of the nematode isoform of an evolutionary conserved Ca2+-activated
K+ channel, SLO-1. To test this at the molecular level we compared the actions of emodep-
side at heterologously expressed SLO-1 alpha subunit orthologues from nematode (Cae-
norhabditis elegans), Drosophilamelanogaster and human using whole cell voltage clamp.
Intriguingly we found that emodepside modulated nematode (Ce slo-1), insect (Drosophila,
Dm slo) and human (hum kcnma1)SLO channels but that there are discrete differences in
the features of the modulation that are consistent with its anthelmintic efficacy. Nematode
SLO-1 currents required 100 μM intracellular Ca2+ and were strongly facilitated by emodep-
side (100 nM; +73.0 ± 17.4%; n = 9; p<0.001). Drosophila Slo currents on the other hand
were activated by emodepside (10 μM) in the presence of 52 nM Ca2+ but were inhibited in
the presence of 290 nM Ca2+ and exhibited a characteristic loss of rectification. Human Slo
required 300nM Ca2+ and emodepside transiently facilitated currents (100nM; +33.5 ± 9%;
n = 8; p<0.05) followed by a sustained inhibition (-52.6 ± 9.8%; n = 8; p<0.001). This first
cross phyla comparison of the actions of emodepside at nematode, insect and human chan-
nels provides new mechanistic insight into the compound’s complex modulation of SLO
channels. Consistent with whole organism behavioural studies on C. elegans, it indicates its
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anthelmintic action derives from a strong activation of SLO current, not observed in the
human channel. These data provide an important benchmark for the wider deployment of
emodepside as an anthelmintic treatment.
Author Summary
Filarial diseases affect an estimated 200 million people and the Drugs for Neglected Dis-
eases initiative (DNDi) has identified development of macrofilaricidal drugs as a priority.
Emodepside, currently used in companion animals, paralyses adult filarial worms and
may address this unmet need for human medicine. Its receptor is an evolutionary con-
served Ca2+-activated K+ channel, SLO-1. In this paper we address an important knowl-
edge gap in terms of understanding the interaction of emodepside with its target receptor
SLO-1 in nematodes in comparison to the human orthologue KCNMA1 and provide the
first cross phyla analysis of the interaction of emodepside with slo channels, in nematode,
insect and human. Intriguingly, this shows that emodepside modulates slo/BK currents
from heterologously expressed channels from all three organisms, however there are dis-
crete differences in the feature of modulation; only the nematode channel exhibits a sus-
tained facilitation by emodepside. This is consistent with the effects of emodepside on C.
elegans behaviour and indicates that this differential action of emodepside on the nema-
tode channel likely underlies its potent anthelmintic effects. These data provide an impor-
tant benchmark for the wider deployment of emodepside as an anthelmintic treatment.
Introduction
Emodepside is a cyclooctadepsipeptide compound introduced into veterinary medicine for the
treatment of nematode infections in companion animals [1,2]. It inhibits nematode develop-
ment [3] and elicits profound impairment of neuromuscular function [4,5]. Recently there has
been interest in the use of emodepside for the treatment of human helminthiases [6]. In partic-
ular its toxicity to adult filarial worms [7] has raised the prospect of it providing a much needed
macrofilaricidal anthelmintic drug for the treatment of filarial diseases.
Investigation of the mode of action of emodepside revealed two targets, a latrophilin recep-
tor [8,9] and a Ca2+-activated K+ channel SLO-1 [10] of which the latter appears to be the most
important in terms of the efficacy of the compound at a whole organism level [10–13].
SLO-1 belongs to an evolutionary conserved family of K+ channels that are activated by cell
depolarisation and cytosolic calcium. The first member of the family slowpoke (slo) was identi-
fied in the fruit fly Drosophila melanogaster [14] and the K+ channel was shown to have an
unusually large conductance which prompted the name BK for ‘big K+ conductance’. slo/BK
channels were subsequently found across the animal phyla, spanning nematodes to human
[15]. Their dual regulation by membrane voltage and intracellular Ca2+ imparts a phylogeneti-
cally conserved role in regulating cell excitability (9).
SLO channels have been extensively studied in the model genetic organism, the nematode
Caenorhabditis elegans [13,16,17] and it has provided an excellent experimental platform in
which to investigate the mode of action [10] and selective toxicity [12,18] of emodepside.
These studies have expressed slo/BK channels from parasitic nematodes and human in a C. ele-
gans slo-1mutant to evaluate their role in conferring sensitivity to emodepside. These whole
organism studies are consistent with the conclusion that emodepside preferentially activates
Cross-Phyla Study of Emodepside Effect on Slo Currents
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the nematode isoforms of the calcium-activated K+ channel. More recently it has been shown
that emodepside activates C. elegans SLO-1A heterologously expressed in Xenopus oocytes
[19]. However a direct comparison of the effects of emodepside on heterologously expressed
slo/BK channels from different phyla is currently lacking. This information is important to
underpin its extended use as an anthelmintic drug.
To address this knowledge gap, here we provide the first cross phyla study on the actions of
emodepside, on nematode, insect and human channels. We used heterologous expression of
recombinant C. elegans, Drosophila and human BK/SLO channels to demonstrate that emo-
depside directly modulates the nematode, insect and mammalian channels. Importantly we
provide mechanistic insight which reveals a differential action of emodepside on the nematode
channel, a profound facilitation, which underpins its selective toxicity as an anthelmintic.
Taken together our data further support the wider use of emodepside for the treatment of hel-
minthiases. Moreover, they are consistent with BK/SLO channels harbouring a cyclooctadep-
sidpeptide pharmacophore which could be exploited for further applications in veterinary and
human medicine.
Methods
Vectors for expression of slo/BK channels in HEK(Human Embryonic
Kidney) 293 or CHO (Chinese Hamster Ovary) cells
C. elegans slo-1a (Ce slo-1) was cloned into a pIRES2-eGFP vector (BD biosciences, Clontech)
for expression in HEK293 cells. slo-1a cDNA was PCR amplified from the pBK3.1 vector [16]
and cloned into the pIRES2-eGFP vector.
In preliminary experiments we found that high concentrations of pIRES2-eGFP::slo-1a
cDNA were required to obtain functional expression of SLO-1 currents in HEK293 cells. Due
to simultaneous transcription of egfp this resulted in high levels of expression of eGFP and cells
looked unhealthy (rounded, with dark inclusions) and were not suitable for reliable electro-
physiology. Therefore, we removed the eGFP coding sequence from the pIRES2-eGFP::slo-1a
vector and instead used a separate plasmid, at lower concentration, to transfect the cells with
the eGFP transformation marker.
The mammalian orthologue for SLO-1a (NP_001024259), KCNMA1 was identified using
Ensembl orthologue definitions as previously described [18]. It predicts 20 protein-coding
transcripts. The protein product of Ensembl transcript KCNMA1-001 (peptide ENSP00000
286627) corresponds to KCNMA1 variant 2/isoform b in the NCBI database (NP_002238).
The alignment and identity of KCNMA1 isoform b with C. elegans slo-1a is described in Cris-
ford et al, [18]The transcript encoding this isoform (NM_002247) was available to purchase
from OriGene Technologies, USA. The kcnma1 gene is in the pCMV6-XL4 vector behind a
mammalian cell specific pCMV promoter suitable for expression in HEK293 cells.
Drosophila slo (DmSlo) was amplified by PCR with pfu Polymerase (Stratagene) from adult
Drosophila melanogaster cDNA (Clontech) and cloned into pcDNA3.1 (Invitrogen).
HEK293 cell culture
Human embryonic kidney cells (HEK293) were obtained from European Cell Culture, collec-
tion reference 85120602. Cells were maintained in 25cm2 flasks in Dulbecco's Modified Eagle
Medium (DMEM GlutaMax, Gibco, Life Technologies UK) supplemented with 10% Fetal Calf
Serum (FCS), 1% Penicillin/ Streptomycin (100units/100μg/ml) and L-glutamine (2 mM).
Cells were incubated at 37°C, 5% CO2. HEK293 cells were passaged every 2–3 days (when 70–
80% confluent) and kept for a maximum of 20 passages.
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HEK293 cell transfection
Plasmid DNA was delivered to the cells using jetPEI transfection reagent (Polyplus, Source
Bioscience Autogen, Nottingham, UK). 1 g of DNA to express KCNMA1 or eGFP (KCNMA1
control) was mixed with 4 μl of jetPEI and each 1 μg of DNA to express SLO-1 or eGFP (SLO-1
control) was mixed with 2 μl of jetPEI. Transfections with eGFP DNA for control recordings
were done in the same ratios as the transfections with the genes of interest. Cells were incu-
bated with transfection mixtures for 18 hours at 37°C, 5% CO2. DNA/JetPEI complexes were
then removed and replaced with fresh DMEM/10% FBS. Cells transfected with plasmid DNA
to express SLO-1 were transferred to 30°C, 5% CO2 incubator for 24 hours as this enhanced
heterologous expression of the [20] invertebrate channel in mammalian cells. Cells transfected
with plasmid DNA to express KCNMA1 were maintained at 37°C.
Generation of a stable Drosophila melanogaster Slo (Dm Slo) CHO cell
line
CHO cell line (CHO duk) was obtained from ATCC, code ATCC CRL-9096. For transfection
with plasmid DNA to express Dm Slo CHO cells were passaged to 40% confluence before add-
ing the transfection solution. The transfection solution contained 300 μL OptiMEM (Life Tech-
nologies, Nr.: 31985), 2 μL (6μg) pcDNA3.1 (-)Dm Slo and 9μL FugeneHD (Promega, Nr.:
E2311) and were added to the cells and incubated for 48 hours at 37°C, 5% CO2. The transfec-
tion medium was exchanged for the selection medium which contains additional G418 (2 mg/
ml, Invitrogen, Nr.: 10131), the cells were seeded into 384 well plates (300 cells/well). After a
few weeks, the few surviving cells were tested with a voltage sensitive dye (membrane potential
assay kit Dye B, Molecular Devices Nr.: R80034) for K+ channel expression. Cells from the best
clone (strongest signal in reaction to a 70 mM K+ application in combination with 3 μMCa2+
Ionophor A23187, Sigma Nr.: C7522), were plated out on glass coverslips for testing Dm Slo
channel expression electrophysiologically using whole cell voltage clamp technique (see section
whole cell voltage clamping CHO). After validation of functional Dm Slo channel expression
the best clone was subcloned in 384 well plates (0.7 cells/well) in order to obtain clonal purity.
The clone with the best membrane potential signal was assessed electrophysiologically for Dm
Slo channel function. This generated a final stable CHO cell line expressing the Dm Slo.
Whole cell patch clamping HEK293 cells
Whole cell currents from cells transfected with plasmid DNA to express Ce slo-1 were recorded
48 hours after transfection. Whole cell currents from cells transfected with plasmid DNA to
express KCNMA1 were recorded 24 hours after transfection. Cells were transferred to the per-
fusion chamber and recordings were made at room temperature (20 to 25°C).
Patch pipettes (4–6 MO) were filled with internal solution containing 140 mM KCl, 1 mM
MgCl2, 2 mM Na2ATP, 3.3 mM CaCl2, 10 mMHepes, 5 mM EGTA, pH 7.2 (adjusted with
KOH), in which free [Ca2+] was 300 nM. The calculation of free Ca2+ was made by using the
software “MaxChelator Sliders”(from C. Patton, Stanford University) and a dissociation con-
stant for the Ca2+-EGTA-complex of 90nM (pH 7.3) [21,22]. For 100 μM free [Ca2+] internal
solution contained: 140 mM KCl, 1.2 mMMgCl2, 2 mM Na2ATP, 5.4 mM CaCl2, 10 mM
Hepes, 5 mM EGTA. Osmolarity ranged from 280 to 300 mOsm. The external solution con-
tained 137 mMNaCl, 5.9 mM KCl, 2.2 mM CaCl2, 1.2 mMMgCl2, 10 mMHepes, 14 mM Glu-
cose, pH 7.4 (adjusted with NaOH). Osmolarity was 300 mOsm.
Transiently transfected cells were identified by eGFP fluorescence. Whole cell currents were
evoked by 50 ms voltage steps from -100 mV to +90 mV in 10 mV increments from a holding
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potential of -60 mV. Alternatively, whole cell currents were evoked by 50 ms voltage steps from
-80 mV to +170 mV in 10 mV increments from a holding potential of -60 mV.
Cells were perfused with extracellular solution, with or without drug, at a rate of 0.5–0.8 ml
min-1 using a parallel tubing perfusion system driven by an electric pump. The time taken for
the drug to access the vicinity of the cell being recorded was 30 to 45 s from the initiation of
perfusion. Depolarising voltage steps were applied from -60 mV to +70 mV for 100 ms cells
were held at -60 mV for 10 s between depolarising steps in order to analyse the current-voltage
relationship during drug applications. Drug or vehicle (control) application was initiated when
the current elicited by the voltage steps from -60 mV to +70 mV reached a steady state (at least
six current-voltage responses overlapped at +70 mV).
Whole cell currents were recorded using an Axopatch 200B amplifier (Axon Instruments,
Foster City, CA) and pClamp 10 software employing Digidata 1440A (Axon Instruments).
Data were filtered (4-pole Bessel) at 1 kHz and digitized at 5 kHz. Current-voltage relationships
were plotted from the plateau of each depolarising step using Graph Pad Prism computer soft-
ware (version 5.0 San Diego, California). The response to progressive depolarising voltage
steps from -60 mV to a maximum of +170 mV was plotted as a time-dependent response. Leak
subtraction voltage-command protocols were not applied. Traces for the whole cell currents
where leak was more than 10% of the whole current were excluded from the analysis.
Whole cell patch clamping CHO cells
Whole cell voltage-clamp was performed on CHO cells stably transfected with the Dm Slo
channel. Patch pipettes (borosilicate glass capillaries, 2.5–3.5 MO) contained (in mM): 150
KCl, 10 HEPES (pH 7.3 adjusted with KOH), 10 K-EGTA, 0, 3, 5, or 7 mM CaCl2. The cells
were placed in a perfusion chamber (2.5ml) at room temperature (22–25°C) and superfused
continuously (flow rate 3 ml min-1) with external bath solution driven by gravity. The fluid in
the chamber renewed every 60 s. The external bath contained (in mM): 150 NaCl, 4 KCl, 2
MgCl2, 2 CaCl2, 10 HEPES (pH 7.3 adjusted with NaOH). Compounds were applied to the
cells using the U-tube reversed flow technique. Currents were recorded from a holding poten-
tial of -70 mV with an L/M-EPC 7 patch clamp amplifier (List, Darmstadt, Germany; pClamp
software, Axon Instruments, Ver. 6.03, Foster City, CA), low-pass Bessel filtered at 3.15 kHz
and digitized at 5 kHz sample rate.
Ca2+ fluorescence measurements in HEK293 cells
HEK293 cells were incubated with 100 μl of 4 μM Fluo-3AM prepared with Pluronic F-27
(Molecular Probes, Life Technologies, UK) at room temperature for 30 min. Following dye
removal cells were further incubated at 37°C, 5% CO2 with 180 μl of 1% Bovine Serum Albu-
min (BSA) per well for 30 min, washed with 200 μl of PBS (phosphate buffered saline) with
subsequent addition of 100 μl of Hank’s Balanced Salt Solution (HBSS) (Gibco, Life Technolo-
gies, UK) containing 10 mM Ca2+. Ca2+ levels in cells before and after the treatment with emo-
depside or ionomycin were then quantified by measuring the Ca2+ fluorescence at excitation of
480p and emission of 525p using FLUO Star OPTIMA. The experiment was repeated at least
three times with independent cell cultures and the data were pooled for analysis.
Drugs
10 mM stock solution of emodepside was prepared freshly for each experiment in 100%
DMSO (Dimethylsulfoxide). Emodepside was diluted in DMSO and then directly into external
solution to give a final concentration of 100 nM, 10 nM and 1 nM (0.01% DMSO). For dissolv-
ing relatively high emodepside concentrations (1 μM and 10 μM) 0.03% Pluronic F68 (Sigma,
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P1300) was added as solvent. For injection studies emodepside was dissolved in 100% DMSO
given a final concentration of 2 mg/ml. Emodepside was provided by Bayer Animal Health,
Monheim Germany. 10 mM stock solution of penitrem A (Enzo Life Sciences, Exeter, UK) was
prepared in 100% DMSO. Aliquots of stock solution were kept at -20°C. The final concentra-
tion of penitrem A was 1 μM (0.01% DMSO). Ionomycin was prepared by diluting 4 μl of iono-
mycin stock (10mM) in 100% DMSO into 36 μl of HBSS. 1 μl of this ionomycin solution was
added to the microtitre cell in 100 μl of HBSS to give a final concentration of 1% DMSO and
10 μM ionomycin. 2% Triton-X 100 was prepared by diluting 10 μl of Triton-X in 490 μl of
HBSS and 10 mM Ca2+ solution, 2.5 μl of this preparation was added per well (volume). For
electrophysiological measurements a 1 mM stock solution of verrucologen (Cfm Oskar Tro-
pitzsch e.K., Marktredwitz, Germany) was prepared in DMSO and diluted into external solu-
tion to give required concentrations between 0.1 pM and 30 μM just before the experiment.
Statistical analysis
Data points in graphs are presented as the mean ± standard error of the mean for the number
of experiments as shown in individual figures. Current-voltage and current-time relationships
were plotted using either Graph Pad 5 software (San Diego, California) or Origin 6.0 Software
(Microcal Software Inc., Northampton, MA, USA). Statistical significance was determined
either by unpaired Student’s t-test, one-way or two-way ANOVA as appropriate; significance
level set at P< 0.05, followed by Bonferroni post-hoc tests as appropriate. Boltzmann analysis
was performed using GraphPad Prism, version 6.05 (San Diego, California) and the equation
G/Gmax = 1/(1+exp((V50-Vm/slope)). Conductance, G, for each membrane potential (Vm) was
calculated using an equilibrium potential for K+ of -80 mV from the equation G = I/Vm-EK.
Gmax was defined as the average maximal conductance for each experimental group. Values are
given with 95% confidence intervals.
Results
In this study we directly tested the hypothesis that emodepside is a modulator of Ca2+ -acti-
vated K+ channels in nematodes, insects and humans and characterised the features of modula-
tion. First we established a heterologous expression assay for each of these channels and
optimised the experimental conditions to record currents of similar amplitudes for the nema-
tode, insect and human channel before progressing to investigate the effect of emodepside.
Establishing conditions for heterologous expression of Ca2+ -activated K
+ channels
Ce slo-1 (C. elegans slo-1) was expressed in HEK293 cells in the presence of different intracellu-
lar Ca2+ concentrations. Voltage-activated K+ currents of very low amplitude were recorded in
300 nM free intracellular Ca2+ (Fig 1A and 1B; mean peak current 0.49 ± 0.05 nA, n = 25) and
were only marginally higher than the current recorded from control eGFP transfected cells
(0.33 ± 0.03 nA; n = 13; P = 0.0192 unpaired Student’s t-test). Previously it has been reported
that C. elegans slo-1 requires micromolar Ca2+ for activation [16,23,24]. Therefore, we tested
the slo-1 transfected cells in the presence of 100 μMCa2+. Under this condition the voltage-
activated K+ currents recorded from HEK293 cells were markedly increased (Fig 1A and 1B;
mean peak current for SLO-1 in 100 μMCa2+ was 3.48 ±0.19 nA; n = 52). Increasing the intra-
cellular Ca2+ to 100μM had no significant effect on the currents recorded from cells expressing
the control egfp plasmid (Fig 1A and 1B; mean peak current at +90 mV 0.30 ± 0.04 nA, n = 14;
P = 0.57 unpaired Student’s t-test compared to egfp expressing cells recorded with 300 nM
Ca2+) indicating that the effect of 100μMCa2+ in facilitating channel activation is specific to
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the slo-1 transfected cells. It is established that mammalian BK channels can be activated by
Ca2+ with a Kd of 0.8–11 μM [25] and as low as 0.5–100 nM [26]. Consistent with this, and in
contrast to the Ca2+ dependence observed for slo-1 transfected cells, we observed robust volt-
age-activated K+ currents from cells expressing kcnma1 with 300 nM intracellular Ca2+ (Fig 1A
and 1B; mean peak current at +90mV of 2.74 ± 0.11nA, n = 50; P<0.001 compared to egfp
alone, unpaired Student’s t-test). Similarly CHO cells expressing Dm Slo (Drosophila melano-
gaster Slo) showed strong activation of voltage-activated K+ currents at low free intracellular
Ca2+ (Fig 2A and 2B) with a threshold around 52 nM and robust activation at 290 nM. There-
fore, in further experiments to characterise all three channels we routinely used 100 μM, 300
nM and 290 nM free intracellular Ca2+ for Ce slo-1, human kcnma1 and Dm Slo respectively in
Fig 1. A comparison of the voltage and Ca2+ -dependent activation of human KCNMA1 andC. elegans SLO-1a. A. Representative traces of currents
recorded from HEK293 cells expressing eGFP alone (control), Ce SLO-1 or hum KCNMA1. Membrane potential was held at -60mV and stepped to between
-100 and +90mV in 10mV increments for 50ms. Free [Ca2+] in the internal solution was 300nM or 100μM as indicated. B. Current-voltage relationship for
whole cell currents recorded from cells expressing eGFP alone (control), Ce SLO-1 or hum KCNMA1 at 300nM or 100μM free intracellular [Ca2+]. Membrane
potential was held at -60mV and stepped to between -100 and +90mV in 10mV increments for 50ms. Data points are the mean ± s.e.mean of ‘n’ cell
recordings (shown in brackets). Currents recorded from Ce SLO-1 in the presence of 300nMCa2+, Ce SLO-1 in the presence of 100μMCa2+ and hum
KCNMA1 in the presence of 300nM Ca2+ were significantly different from eGFP recorded in 300nM and 100μMCa2+; p<0.001, two-way ANOVA with
Bonferroni post-hoc test.
doi:10.1371/journal.pntd.0004062.g001
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order to obtain robust currents of similar amplitude for each of the channels against which to
make the most accurate comparison of the effects of emodepside on the different isoforms of
channel.
We confirmed the identity of the Ce slo-1, kcnma1 and Dm Slo channel currents by testing
their sensitivity to selective BK channel blockers penitrem A [27] or verruculogen [28](Fig 3A
and 3B; Fig 4). Only cells for which a consistent current-voltage relationship was obtained for
the first 2 min of recording were subjected to drug application. For C. elegans SLO-1 in which
recordings were made with 100 μM intracellular Ca2+ such stable recordings were only
Fig 2. Voltage and Ca2+-dependent activation of Drosophila Dm Slo. A. Representative whole cell currents recorded from CHO cells stably expressing
Dm Slo. Membrane potential was held at -70mV and stepped to between -120 and +60mV in 10mV increments for 100ms. Free [Ca2+] in internal solution was
52 nM, 120 nM, 290nM or 12700 nM. B. Current-voltage relationship of Dm Slo whole cell currents expressed in CHO at different free intracellular [Ca2+] as
indicated. Membrane potential was held at -70mV and stepped to between -120 and +60mV in 10mV increments for 100ms. Data points are the mean ± s.e.
mean of ‘n’ cell recordings, as indicated.
doi:10.1371/journal.pntd.0004062.g002
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achieved for 10% of the total number of transfected cells from which whole cell recordings
were made, most likely reflecting the impact that the high Ca2+ concentration has on the
integrity of the cells. Once a stable recording was established the drugs were applied and
recordings were made throughout the drug application for a period of up to 15 min. This was
the maximum duration of recording that could be made for SLO-1 as after this time the
recordings became unstable as indicated by the holding current and the cells were routinely
lost. Visual inspection of the cells indicated a shrunken appearance, presumably due to the
Fig 3. Ce SLO-1 and humKCNMA1 currents are blocked by the BK channel antagonist penitrem A. A. Representative whole cell currents recorded
from HEK293 cells expressing either Ce SLO-1 or hum KCNMA1 before and after penitrem A (1μM) application. Membrane potential was held at -60mV and
stepped to between -100 and +90mV in 10mV increments for 50ms. B. A time-course of steady state Ce SLO-1 and hum KCNMA1 currents at +70mV
(stepped every 10s for 40ms from -60mV holding potential) before and during application of DMSO (0.01%) or penitrem A (1μM). The current response is
shown as a percentage change from the mean of pre-drug current amplitude during the 0 to 2 min time period. An arrow indicates the time point at which the
drug solution reached the chamber with the cells. Free intracellular [Ca2+] was 100μM for Ce SLO-1 and 300nM for hum KCNMA1. Data points are the
mean ± s.e.mean. p<0.0001 for penitrem A inhibited current compared to DMSO treatment, two-way ANOVA with Bonferroni post-hoc tests.
doi:10.1371/journal.pntd.0004062.g003
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high (100 μM) intracellular Ca2+ that was required for these recordings. For SLO-1, the
recordings were interleaved with controls on the same day; control recordings were made
from transfected cells that were perfused with vehicle control (0.01% DMSO). Both SLO-1
and KCNMA1 currents were blocked by penitrem A (1 μM; Fig 3A and 3B). The mean peak
current at +90 mV for SLO-1 was 3.95 ± 0.73 nA before and 0.63 ± 0.17 nA after 10 min of
treatment with penitrem A (n = 7). For KCNMA1 the mean peak current at +90 mV was
2.66 ± 0.20nA before and 0.53 ± 0.09 nA after 10 min of treatment with penitrem A (n = 7).
Similarly, in CHO cells expressing Dm Slo the voltage-activated K+ currents elicited in the
presence of 290 nM free intracellular Ca2+ were completely blocked by the BK channel antago-
nist verruculogen at 3 μM (Fig 4; n = 5) and the dose response curve revealed an IC50 value of
6.2 nM for inhibition of Dm Slo by verruculogen (95% confidence intervals 2.52 to 8.57 nM)
and an IC50 value of 0.5 nM for inhibition of Dm Slo by penitrem A (95% confidence intervals
0.43 t0 12.9 nM; Fig 4).
Fig 4. Dm Slo currents are blocked by the BK channel antagonists verruculogen and penitrem A. Top
panel shows representative traces of Dm Slo whole cell currents stable expressed in CHO cells before and
after verruculogen (3μM) application. Membrane potential was held at -70mV and stepped to between -120
and +60mV in 10mV increments for 100ms. Bottom panel shows dose-response curves for verrucologen
(circles) and penitrem A (squares) on Dm Slo. Membrane potential was held at -70mV. Test pulses to + 60mV
for 100ms. Each data points represent the mean ± s.e. of n = 3 cells.
doi:10.1371/journal.pntd.0004062.g004
Cross-Phyla Study of Emodepside Effect on Slo Currents
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004062 October 5, 2015 10 / 20
Biphasic modulation of human KCNMA1 by emodepside
The same protocol that was optimised to determine the penitrem A inhibition of KCNMA1
was modified to test for an interaction of emodepside with the channels. Thus, for these experi-
ments emodepside (1, 10 or 100 nM) or DMSO (0.01%) was applied to the cells after 2 min ini-
tial baseline recording and recordings were followed for up to a further 23 min i.e. as long as
the stability of the recording permitted. This range of concentrations of emodepside was cho-
sen as the EC50 for the inhibitory effect of emodepside on C. elegans behaviours is between 10
and 100 nM [10,18]. In HEK293 cells expressing KCNMA1 emodepside elicited a biphasic,
concentration-dependent effect on current amplitude (Fig 5A, 5B and 5C). The effect was of a
similar magnitude for 10 nM and 100 nM emodepside but was only statistically significant for
100 nM emodepside. The early facilitation was transient, lasting less than ten min, and fol-
lowed by an inhibition of current amplitude. Again the inhibition was observed at both 10 and
100 nM emodepside but was only statistically significant for 100 nM emodepside. The mean
peak currents for KCNMA1 at +90 mV were increased from 2.94 ± 0.36 nA (n = 8) to
4.31 ± 0.34 nA (n = 8) after 5 min emodepside and were then reduced to 1.67 ± 0.26 nA (n = 7)
after 23 min of emodepside. Whole cell currents recorded from transfected cells treated with
0.01% DMSO did not change significantly over a 25 min time-course. The time-course of the
response to emodepside was slow in onset and slow to reach the peak effect similar to the time-
course of the effect of emodepside reported in other systems [13].
Facilitation of C. elegans SLO-1 by emodepside
Given the effect of 100 nM emodepside on hum KCNMA1 (huma KCNMA1) we decided to
test the effect of this concentration on C. elegans SLO-1 currents. We were constrained to test-
ing this concentration of emodepside rather than a dose range because of the technical diffi-
culty of recording SLO-1 currents from HEK293 cells with 100 μMCa2+. Notably, for Ce SLO-
1 the current amplitude was increased, but not inhibited, by 100 nM emodepside (Fig 6A and
6B). The facilitation followed a slow time-course and continued to increase throughout the
time-course of the experiment (Fig 6B). The mechanisms that might underpin a slow time-
course of action for emodepside, pharmacokinetic versus mechanistic, have previously been
discussed in Holden-Dye et al [13]. The mean peak currents at +90 mV for Ce SLO-1 record-
ings were 2.95 ± 0.35nA before and 4.39 ± 0.55nA after 10 min of treatment with emodepside
(n = 9; Fig 6B) representing a facilitation of 73.0 ± 17.4% (n = 9; p<0.001 compared to DMSO
control). Over the same time-course the 0.01% DMSO control treated transfected cells exhib-
ited mean peak currents at +90 mV of 3.14 ± 0.36nA before DMSO compared to 2.17 ± 0.25nA
after DMSO (n = 5).
Emodepside shifts the voltage activation curve for Ca2+ -activated K+
channels
The voltage activation of Ce SLO-1 and hum KCNMA1 was tested before and during the peak
of the emodepside facilitation (i.e. after 12 min application of 100 nM emodepside for Ce SLO-
1 and after 5 min application of 100nM emodepside for hum KCNMA1; Fig 7). A significant
shift in the voltage activation curve was observed for Ce SLO-1 (p<0.05) after emodepside
treatment and a smaller significant shift for hum KCNMA1 (p<0.05). The data from Fig 7
were subjected to Boltzmann analysis to estimate V50, the membrane potential for half-activa-
tion of the channels using Gmax values of 0.0174, 0.0258, 0.0177 and 0.0253 μS for Ce SLO-1
control, Ce SLO-1 with emodepside, hum KCNMA1 control and hum KCNMA1 with emo-
depside, respectively. For Ce SLO-1 V50 was +49.74 mV (95% confidence intervals 45.46 to
Cross-Phyla Study of Emodepside Effect on Slo Currents
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Fig 5. The biphasic effect of emodepside on humKCNMA1 currents. Time-course analysis of steady
state hum KCNMA1 currents expressed in HEK293 cells at +70mV (stepped every 10s for 40ms from -60mV
holding potential) before and during application of 0.01%DMSO or emodepside. The current response is
shown as a percentage change from the mean of pre-drug current amplitude during the 0 to 2 min time
period. Arrow indicates the time of emodepside application at A. 1nMB. 10nM andC. 100nM. Data points are
Cross-Phyla Study of Emodepside Effect on Slo Currents
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the mean ± s.e.mean. 100nM emodepside had a biphasic effect on hum KCNMA1 currents eliciting a
significant increase between 4 and 8 min application (p<0.05) and a significant decrease after 20 min
application (p<0.001); two-way ANOVA with Bonferroni post-hoc tests.
doi:10.1371/journal.pntd.0004062.g005
Fig 6. Emodepside increases Ce SLO-1 currents. A. Representative traces of Ce SLO-1 whole cell
currents expressed in HEK293 cells before (top trace) and (bottom trace) 12 min after emodepside (100nM)
application. Membrane potential was held at -60mV and stepped to between -100 and +90mV in 10mV
increments for 50ms. B. A time-course of steady state Ce SLO-1 currents expressed in HEK293 cells at
+70mV (stepped every 10s for 40ms from -60mV holding potential) before and during application of 0.01%
DMSO or 100nM emodepside. The current response is shown as a percentage change from the mean of pre-
drug current amplitude during the 0 to 2 min time period. Arrow indicates the time of emodepside application.
Data points are the mean ± s.e.mean. Emodepside significantly increased the amplitude of the Ce SLO-1
currents, p<0.001, two-way ANOVAwith Bonferroni post-hoc tests.
doi:10.1371/journal.pntd.0004062.g006
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54.01; V slope 20.66) and this was shifted in the presence of emodepside to +32.95 mV (95%
confidence intervals 28.82 to 37.07; Vslope 28.36). For hum KCNMA1 the V50 was +56.51 mV
(95% confidence intervals 52.82 to 60.20; Vslope 17.45) which was unchanged in the presence
of emodepside, + 57.88 mV (95% confidence intervals 54.09 to 61.68; Vslope 17.12). This anal-
ysis confirms the selective effect of emodepside on the voltage-activation for Ce SLO-1.
The effects of emodepside on Dm Slo
Recordings made from CHO cells expressing Dm Slo revealed complex effects of emodepside
(10 μM). In the presence of low (52 nM) Ca2+, a situation in which voltage steps do not activate
K+ currents, emodepside revealed a K+ current (Fig 8A, middle panel). However, in the pres-
ence of higher (290 nM) Ca2+, a situation in which the voltage steps generate typical outwardly
rectifying K+ currents, emodepside inhibited the amplitude of the outward current (Fig 8B, bot-
tom panel). We also noted, that in the presence of either 52 nM or 290 nM Ca2+, emodepside
caused rapid membrane hyperpolarisation (n = 15; emodepside shifted the resting membrane
Fig 7. The effect of emodepside on voltage-activation of Ce SLO-1 and humKCNMA1. Analysis of the
current-voltage relationship of the data sets shown in Fig 6 and Fig 7 for Ce SLO-1 and hum KCNMA1 whole
cell currents expressed in HEK293 cells before and after treatment with emodepside (100nM). Ce SLO-1
currents were recorded before and 12 min after emodepside application. Hum KCNMA1 currents were
recorded before and 5 min after emodepside application. Membrane potential was held at -60mV and
stepped to between -100 and +90mV in 10mV increments for 50ms. Data points are the mean ± s.e.mean of
n = 9 for Ce SLO-1 and n = 8 for hum KCNMA1. The amplitude of Ce SLO-1 currents in the presence of
100nM emodepside was significantly greater than currents recorded in the absence of emodepside between
+20 and +90mV and for hum KCNMA1 was significantly greater than currents recorded in the absence of
emodepside between +70 and +90mV; p<0.05; two-way ANOVA with Bonferroni post-hoc tests.
doi:10.1371/journal.pntd.0004062.g007
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potential from -55 ± 6 to -79 ± 3 mV, mean ± s.e.m.). During recordings made in current
clamp mode we observed that a few minutes after emodepside application the membrane
potentials reach steady-state values which were close to the K+ equilibrium potential (Em =
-79.8 ± 6.5 mV, n = 15; EK = -91.2 mV). Moreover, test pulses in the presence of emodepside
for both 52 nM and 290 nM Ca2+ revealed linear current-voltage behaviour over the voltage
range from -120 to + 60 mV in all experiments (n = 15; Fig 8A and 8B). Whilst activation and
inhibition of the voltage-activated K+ current by emodepside was modified by the Ca2+ concen-
tration, the emodepside-induced modification of the current-voltage relationship was largely
independent of intracellular Ca2+ concentration. Thus in the presence of low intracellular Ca2+
(52 nM) where the Dm Slo channel was closed at most voltages and also at higher intracellular
Ca2+ (e.g. 290nM) where the Dm Slo channel shows outward rectification, emodepside consis-
tently induced a linear current-voltage behaviour of the Dm Slo channel (Fig 8B) indicating a
reduction in the rectifying properties of the channel without any shift in reversal potential.
Emodepside does not increase intracellular Ca2+ in HEK293 cells
It was important to substantiate that the actions of emodepside are mediated via a direct inter-
action with the channel rather than indirectly via an increase in intracellular Ca2+, possibly by
acting as an ionophore [29]. In order to test this HEK293 cells were loaded with the Ca2+ fluor-
ophore Fluo-3,AM and exposed to emodepside. Whilst a positive control, treating cells with
ionomycin (10 μM), elicited a robust increase in Ca2+ fluorescence, no increase in intracellular
Ca2+ was observed even at high micromolar concentrations of emodepside (Fig 9).
Fig 8. Intracellular Ca2+ ions are required for emodepside activation of Dm Slo. A. Representative traces of Dm Slo whole cell currents stable
expressed in CHO cells before (left hand traces) and after (right hand traces) emodepside (10 μM) application at different free intracellular [Ca2+] (“0 nM”, 52
nM and 290 nM as indicated). Emodepside was applied for 10 min for experiments with low free intracellular [Ca2+] (“0 nM” and 52 nM). Membrane potential
was held at -70 mV and stepped to between -120 and +60 mV in 10 mV increments for 100 ms.B. Current-voltage relationship of Dm Slo whole cell currents
after emodepside application at two different free intracellular Ca2+ concentrations, as indicated. Membrane potential was held at -70 mV and stepped to
between -120 and +60 mV in 10 mV increments for 100 ms. Data points are the mean ± s.e.mean of n cell recordings.
doi:10.1371/journal.pntd.0004062.g008
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Discussion
In this study we have investigated the cyclooctadepsipeptide compound emodepside as a novel
modulator of the BK/SLO-1 Ca2+ -activated K+ channels from nematode, insect and human.
We established the requisite Ca2+ concentration for channel activation in order to establish
experimental conditions in which to investigate the ability of emodepside to act as a channel
modulator. The nematode Ca2+ -activated K+ channel differs from the insect and human chan-
nel in terms of its Ca2+ sensitivity. Thus we observed that 100μMCa2+ was required to record
Ce SLO-1 currents in contrast to 290–300 nM for Dm Slo and hum KCNMA1. This is consis-
tent with the micromolar concentration of Ca2+ used to characterise the C. elegans SLO-1 chan-
nel in Xenopus oocyte expression studies [16] and patch clamp recordings from C. elegans
body wall muscle which showed that 100μM internal Ca2+ concentration is required to observe
SLO-1 channel openings [30]. The gating of the channel by Ca2+ is regulated by the gating ring
[31] and thus these observations suggest functional differences between the nematode channel
compared to human and insect in this region. The requirement of the nematode channel for
high micromolar concentrations of Ca2+ for activation indicates that physiological regulation
may be achieved only by close juxtaposition of the K+ channel with voltage-gated Ca2+ chan-
nels in the plasma membrane so that local, transient elevations in cytosolic Ca2+ may activate
the channel as suggested by the Ca2+ domain hypothesis [32].
Emodepside showed efficacy at C. elegans SLO-1 and human KCNMA1 channels heterolo-
gously expressed in HEK293 cells. However, whilst emodepside affected both SLO-1 and
KCNMA1 currents, there were distinct differences in the effect observed. Emodepside
enhanced C. elegans SLO-1 currents by up to 80% and shifted the voltage-activation to a lower
threshold. This resembles the effect of increased Ca2+ concentration on the voltage-activation
range of BK channels [16,23,24,33]. In contrast, KCNMA1 currents were subject to biphasic
modulation by emodepside, an initial transient facilitation followed by a more prolonged
inhibition. Moreover, the maximal facilitation exerted by 100 nM emodepside was only 30%,
considerably less than that observed for SLO-1. This difference in the efficacy of direct
Fig 9. Emodepside does not increase cytosolic Ca2+ in HEK293 cells.Ca2+ fluorescence measured in
HEK293 cells loaded with Fluo-3, AM dye after treatment with 1% DMSO (control), 100μM, 10μM, 1μM and
100nM emodepside (1% DMSO) or ionomycin (1% DMSO). The Ca2+ fluorescence was measured at
excitation of 480p and emission of 525p in the FLUO Star OPTIMAmachine. The readings for each treatment
were taken in triplicate. Data were pooled from at least three independent experiments and are shown as
mean ± s.e.mean.
doi:10.1371/journal.pntd.0004062.g009
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modulation of the nematode and the human channel by emodepside is consistent with the
selective toxicity of the compound as an anthelmintic. There is corroboration for this from
experiments in which either nematode slo-1 or human kcnma1 were expressed in C. elegans
slo-1 null mutants which were otherwise insensitive to emodepside. Whilst expression of nem-
atode slo-1 conferred sensitivity to emodepside on the slo-1 null mutants [12,18], 10 to 100
fold higher concentrations of emodepside were required to impair mobility in transgenic lines
expressing the human channel [18]. We also noted that the qualitative features of the impaired
mobility caused by emodepside in the lines expressing the human channel were different from
the effects seen in lines expressing C. elegans slo-1. In the latter a flaccid paralysis was observed
when worms were exposed to low concentrations of emodepside and this effect was phe-
nocopied by a slo-1 gain of function mutant consistent with potent activation of the channel
by emodepside [11]. In contrast, micromolar concentrations of emodepside applied to C. ele-
gans expressing the human channel KCNMA1 impaired mobility but did not elicit a flaccid
paralysis [18]. This led us to suggest that emodepside at micromolar concentrations is an
inhibitor of the mammalian channel [18] and this is directly supported by the inhibition of
KCNMA1 currents observed here. Whilst the inhibition of KCNMA1 by emodepside may be
of relevance in predicting side-effects that might be encountered in its future use in tropical
medicine.
The experiments with Dm Slo provide evidence for an additional effect of emodepside on
Ca2+ -activated K+ channels, namely an ability to diminish the rectifying properties of the
channel. This effect of emodepside on Dm Slo was independent of the intracellular Ca2+ con-
centration. Thus, in either low or high Ca2+, emodepside exposure led to the appearance of
inward current i.e. there was a loss of the characteristic outward rectifying properties of the
channel. It will be interesting to explore whether this phenomenon is observed in isoforms of
slo channels from species of nematodes other than C. elegans.
The effect of emodepside on nematode muscle has been extensively investigated [4,9] and
the observations made from muscle recordings are consistent with those from the recombinant
expressed channels described here. Electrophysiological studies on the parasitic nematode
Ascaris suum have shown that a cyclooctadepsipeptide compound, PF1022A, causes a Ca2+
and K+-dependent relaxation of body wall muscle [4]. Latterly it was shown that emodepside
increases activation of voltage-dependent K+ currents in the muscle of A. suum [5], again con-
sistent with the shift in voltage-activation seen in heterologously expressed slo-1 observed in
this study. BK channels, including C. elegans SLO-1, assemble with accessory subunits in vivo
and it is possible these may impact on emodepside modulation [24] but the similar actions of
emodepside on the heterologously expressed channels and currents recorded from native tissue
argue that this is unlikely to play a significant role.
Our observations, and previous reports, indicate that the modulation of the Ca2+ -activated
K+ channels in HEK293 cells by emodepside cannot be ascribed to an elevation of intracellular
Ca2+. The parent compound for emodepside, the cyclooctadepsipeptide PF1022A, does not
increase intracellular Ca2+ in CaCo-2 cells [34]. Here we conducted a similar study on HEK293
cells and showed that a supramaximal concentration of emodepside (100μM) had no signifi-
cant effect on the intracellular concentration of Ca2+. There is evidence from A. suum that in
vivo emodepside may act indirectly to modulate SLO-1 via an intracellular signalling cascade
involving nitric oxide and protein kinase C [5]. However, given that we have shown that emo-
depside differentially modulates Ce SLO-1, Dm Slo and hum KCNMA1 expressed in HEK293
cells, this is an unlikely explanation for the modulation we have observed. Whilst it cannot be
discounted that additional indirect mechanisms might operate in vivo, our data indicate that
emodepside exerts a modulatory action on SLO-1 and KCNMA1 that is independent of a
change in intracellular Ca2+ and likely reflects a direct modulation of the channel.
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Taken together, our data substantiate a direct interaction of emodepside with C. elegans slo-
1 [19]. This first cross-phyla analysis of C. elegans, human and Drosophila slo/BK indicate a
complex modulation of these Ca2+ -activated K+ channels by emodepside in which only the
nematode channel exhibits a marked facilitation. This is underpinned by a shift in voltage-acti-
vation and provides molecular insight into its potency as an anthelmintic. The data reinforce
the impetus to investigate the utility of this compound, or related drugs which target slo chan-
nels, for the treatment of human helminthiases. Recently it has been shown that there is a syn-
ergistic action of the filaricidal compound diethylcarbamazine with emodepside on Ascaris
suummuscle slo currents and it would be interesting to investigate the mechanism of this in
heterologously expressed slo channels [35]. From a broader perspective, the effects of emodep-
side reported here show that the cyclooctadepsipeptides provide a route to understanding a
new pharmacophore harboured by BK/SLO-1 channels [13] which has important relevance for
the therapeutic exploitation of this target.
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